GAD1 and aceruloplasminemia: Autoantibodies directed against GAD (anti GAD-Ab) have been described in patients with insulin-dependent diabetes mellitus, stiff-person syndrome, epilepsy and in a few patients with late-onset cerebellar ataxia [92–95].